Tag Archive | "Eli Lilly"

Transition Therapeutics licenses drug candidate from Eli Lilly

Tags: ,

Transition Therapeutics announced its wholly-owned subsidiary, Transition Therapeutics Ireland Limited, has exclusively licensed worldwide rights to a novel small molecule drug candidate ("TT701") from Eli Lilly and Company. Read the full story

Lilly snags rights to Erbitux from BMS

Tags: , , ,

Eli Lilly and Bristol-Myers Squibb announced that the companies have agreed to transfer rights to Erbitux (cetuximab) in North America Read the full story

Eli Lilly and Hanmi partner for HM71224

Tags: , ,

Eli Lilly and Hanmi Pharmaceutical have entered into an exclusive license and collaboration agreement for the development and commercialization of Hanmi's oral Bruton's tyrosine kinase (BTK) inhibitor, HM71224 Read the full story

Eli Lilly and Innovent in pact for three cancer treatments

Tags: , ,

Eli Lilly and Innovent Biologics announced one of the largest biotech drug development collaborations in China to date between a multi-national and domestic company Read the full story

Cerecor gains rights to KOR antagonist from Lilly

Tags: , ,

Cerecor has acquired exclusive, worldwide rights from Eli Lilly to develop and commercialize LY2456302 Read the full story

Eli Lilly and BMS study Opdivo combined with galunisertib

Tags: , , ,

Bristol-Myers Squibb and Eli Lilly announced a clinical trial collaboration to evaluate the safety, tolerability and preliminary efficacy of Bristol-Myers Squibb’s immunotherapy Opdivo (nivolumab) in combination with Lilly’s galunisertib Read the full story

Eli Lilly and Merck study Keytruda combinations

Tags: , , ,

Merck and Eli Lilly announced an oncology clinical trial collaboration to evaluate the safety, tolerability and efficacy of KEYTRUDA (pembrolizumab), Merck’s anti-PD-1 therapy, in combination with Lilly compounds in multiple clinical trials Read the full story

Eli Lilly , Uni of Surrey are pharma partners for diabetes treatment

Tags: , ,

Eli, Lilly and Company pharma partners on a five-year research partnership with the University of Surrey to study health outcomes, focusing on the effects of treatment in people with type 2 diabetes, which affects about 95 percent of those with the disease. Read the full story

Eli Lilly and Adocia in BioChaperone Lispro pact

Tags: , ,

Eli Lilly and Adocia announced a worldwide licensing collaboration focused on developing an ultra-rapid insulin, known as BioChaperone Lispro Read the full story

Eli Lilly, Anthem and HealthCore pharma partners to improve health outcomes

Tags: , , ,

Eli Lilly and Company, Anthem, Inc. and HealthCore pharma partners for a five-year, real-world evidence research collaboration intended to improve health outcomes for patients. Read the full story